2024-03-28T17:04:39Z
https://nagoya.repo.nii.ac.jp/oai
oai:nagoya.repo.nii.ac.jp:00030093
2023-11-16T02:43:22Z
499:508:509:2504
High-flow nasal cannula therapy for acute respiratory failure in patients with interstitial pneumonia: a retrospective observational study
Omote, Norihito
Matsuda, Naoyuki
Hashimoto, Naozumi
Nishida, Kazuki
Sakamoto, Koji
Ando, Akira
Nakahara, Yoshio
Nishikimi, Mitsuaki
Higashi, Michiko
Matsui, Shigeyuki
Hasegawa, Yoshinori
open access
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
critical care
pulmonary fibrosis
respiratory failure
nasal cannula
High-flow nasal cannula (HFNC) oxygen is a therapy that has demonstrated survival benefits in acute respiratory failure (ARF). However, the role of HFNC in ARF due to interstitial pneumonia (IP) is unknown. The aim of this study was to compare the effects of HFNC therapy and non-invasive positive pressure ventilation (NPPV) in ARF due to IP. This retrospective observational study included 32 patients with ARF due to IP who were treated with HFNC (n = 13) or NPPV (n = 19). The clinical characteristics, intubation rate and 30-day mortality were analyzed and compared between the HFNC group and the NPPV group. Predictors of 30-day mortality were evaluated using a logistic regression model. HFNC group showed higher mean arterial blood pressure (median 92 mmHg; HFNC group vs 74 mmHg; NPPV group) and lower APACHEII score (median 22; HFNC group vs 27; NPPV group) than NPPV group. There was no significant difference in the intubation rate at day 30 between the HFNC group and the NPPV group (8% vs 37%: p = 0.069); the mortality rate at 30 days was 23% and 63%, respectively. HFNC therapy was a significant determinant of 30-day mortality in univariate analysis, and was confirmed to be an independent significant determinant of 30-day mortality in multivariate analysis (odds ratio, 0.148; 95% confidence interval, 0.025–0.880; p = 0.036). Our findings suggest that HFNC therapy can be a possible option for respiratory management in ARF due to IP. The results observed here warrant further investigation of HFNC therapy in randomized control trials.
Nagoya University Graduate School of Medicine, School of Medicine
2020-05
eng
departmental bulletin paper
VoR
https://doi.org/10.18999/nagjms.82.2.301
http://hdl.handle.net/2237/00032279
https://nagoya.repo.nii.ac.jp/records/30093
10.18999/nagjms.82.2.301
http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/822.html
2186-3326
0027-7622
Nagoya Journal of Medical Science
82
2
301
313
https://nagoya.repo.nii.ac.jp/record/30093/files/14_Omote.pdf
application/pdf
798.2 kB
2020-06-01